TriSalus Life Sciences, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$45M
Cost of Revenue
$7M
Gross Profit
$38M
R&D
$15M
D&A
$626K
Operating Income
$-27M
EBITDA
$-26M
Interest Expense
$6M
Interest Income
$555K
Other Income/Expense
$-7M
Pretax Income
$-39M
Tax Provision
$7K
Net Income
$-39M
Gross Margin
84.6%
Operating Margin
-59.7%
Net Margin
-86.9%
Effective Tax Rate
-0.0%
Deferred Tax Assets
—
DTA Valuation Allowance
$69M
NOL Carryforwards
$54M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
3.2%
Operating Lease Cost
$310K
Revenue YoY Variation
53.4%
Income YoY Variation
25.5%